In less than three years, privately held Immune Pharmaceuticals has matured from a start-up launched with a single monoclonal antibody (MAb) licensed from Canada's iCo Therapeutics Inc. into a biotech capable of absorbing the assets of publicly traded EpiCept Corp. in an all-stock deal. Read More
"The phenotype we describe as cancer is really related to a loss of growth control," Owen Witte told BioWorld Today. "Most frequently, we think of [that loss] as occurring in the cells themselves." Read More
Updated regulations by the U.S. Small Business Administration (SBA) regarding the size and eligibility for Small Business Innovation Research (SBIR) and Small Business Technology Transfer programs may make the programs significantly more competitive when they take effect Jan. 28. Read More
• Tonix Pharmaceuticals Holding Corp., of New York, raised $1 million in gross proceeds from a private placement offering with Technology Partners, a life science venture capital firm. Together with the closing of a prior tranche of the private placement of $2.4 million disclosed earlier this month, that constitutes the final closing of a $3.4 million private placement. Read More
• Auxilium Pharmaceuticals Inc., of Malvern, Pa., said its supplemental Biologics License Application for Xiaflex (collagenase clostridium histolyticum), a therapy for the potential treatment of Peyronie's disease (PD) has been accepted for filing and granted standard review status by the FDA. Read More
• Synergy Pharmaceuticals Inc., of New York, said dosing has commenced in a Phase IIb trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome (IBS-C). The 350-patient trial is being conducted at 70 sites in the U.S. Participants with IBS-C will be treated with one of four doses of plecanatide (0.3, 1, 3 or 9 mg) or placebo, taken once daily over a period of 12 weeks. Read More
